Table 3.
Clinical and biochemical characteristics in subjects without diabetes, or obesity or metabolic syndrome and in statin non users according to the presence or absence of NAFLD
| |
Subjects w/o diabetes |
Subjects w/o obesity^ |
Subjects w/o MetS |
Subjects w/o statin use |
||||
|---|---|---|---|---|---|---|---|---|
| Nafld (144) | no-Nafld (43) | Nafld (85) | no-Nafld (39) | Nafld (73) | no-Nafld (41) | Nafld (139) | no-Nafld (28) | |
| Age (yrs) |
52,1 ± 12,7 |
54,4 ± 14 |
55,0 ± 13,0 |
55,0 ± 14,7 |
50,1 ± 13,1 |
54,7 ± 13,0 |
50,8 ± 11,8 |
53,0 ± 15,9 |
| Male gender (%) |
33,3 |
34,9 |
23,8 |
34,2 |
31,8 |
30,6 |
36,0 |
39,3 |
| BMI |
30,9 ± 5,6 |
26,9 ± 3,7 *** |
26,6 ± 2,3 |
25,2 ± 2,0*** |
29,5 ± 5,7 |
26,5 ± 3,5** |
31,0 ± 5,8 |
27,2 ± 3,9*** |
| Urinary 8-iso-PGF2α (pg/mg creatinine) |
703,4 ± 117,9 |
634,1 ± 106,7*** |
626,6 ± 81,5 |
583,6 ± 102,7* |
672,1 ± 123,0 |
619,3 ± 95,1* |
711,6 ± 133 |
627,5 ± 147,9** |
| sNOX2-dp (pg/ml) |
56,4 ± 13,8 |
49,9 ± 8,9*** |
49,4 ± 12,9 |
45,8 ± 8,9 |
54,0 ± 13,3 |
48,4 ± 8,3* |
57,5 ± 14,1 |
47,5 ± 10,7*** |
| Adiponectin (ng/ml) |
8,5 (5,5/12) |
13,5 (7,5/15)*** |
12,5 (10,5/14) |
13,5 (12,5/14,5)** |
10,5 (6,2/13,6) |
13,0 (6,5/14)* |
7,5 (5/11,5) |
13,5 (6,8/15)*** |
| Cytokeratin-18 (mIU/ml) |
174,5 (136/189) |
130,0 (125/175)** |
149,0 (125/179) |
126,0 (110/165)* |
161,5 (125/180 |
165,0 (125/178) |
179,0 (145/190) |
140,0 (125/179)** |
| ALT (IU/L) |
26 (20/40) |
20 (15/27)*** |
34 (23/42) |
15 (13/24)*** |
26 (19/27) |
18 (14/27)** |
27 (20/40) |
18 (14/27)*** |
| GGT (IU/L) |
25 (17/40)* |
20 (14/28) |
30 (20/52) |
21 (16/23)** |
23 (16/10) |
21 (18/36) |
25 (17/44)* |
21 (13/30) |
| HOMA_IR |
2,9 (2,1/4,5) |
1,8 (1,2/2,1)*** |
2,8 (1,8/4,3) |
2,0 (1,6/3,2) |
2,6 (1,7/3,4) |
1,8 (1,5/2,1)* |
3,1 (2,2/5,5) |
1,8 (1,1/2,1)*** |
| MetS§ (%) |
57,0 |
12,5*** |
51,8 |
19,4*** |
0 |
0 |
57,8 |
16,0*** |
| High Fasting Glucose§ (%) |
32,9 |
19,5 |
44,0 |
30,6 |
15,2 |
13,9 |
41,3 |
23,1 |
| High Triglycerides§ (%) |
44,8 |
11,9*** |
39,3 |
16,2* |
7,6 |
13,9 |
40,9 |
11,1** |
| High Waist Circumference§ (%) |
78,2 |
43,9*** |
55,4 |
27,0** |
59,1 |
38,9 |
80 |
46,2*** |
| Low C-HDL§ (%) |
35,7 |
16,7* |
31,0 |
21,6 |
6,1 |
13,9 |
37,2 |
14,8* |
| High Blood Pressure§ (%) |
79,0 |
74,4 |
81,0 |
73,7 |
69,7 |
75,0 |
80,3 |
75,0 |
| Diabetes (%) |
0 |
0 |
21,4 |
15,8 |
7,6 |
2,8 |
20,1 |
7,1 |
| Statin use (%) | 22,9 | 39,5* | 31,0 | 47,4 | 13,6 | 41,7** | 0 | 0 |
*p< ,05; **p< ,01; ***p< ,001; §According to ATPIII modified criteria (Ref. 30); ^BMI > 30.0.